Novo Nordisk’s study showing a new drug wasn’t as good as a rival’s led one sell-side analyst to downgrade the stock for the first time in five years.
Analyst says he’s thrown in the towel on Novo Nordisk after latest setback
Related Posts
Popular News
Latest News
Strategy Makes 100th Bitcoin Buy, Holdings Reach 717,722 BTC
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure Bitcoin treasury company Strategy has completed a...
Oil prices hover near seven-month highs on US-Iran tensions
Oil prices hover near seven-month highs on US-Iran tensions
The Tallest Buildings in the World
The tallest buildings in the world have always been symbols of human ambition, engineering feats that reshape city skylines, and...
Bitcoin Investment Thesis Still Intact Despite ETF Exit, Analysis Says.
Bitcoin (BTC) will see “purification” as a new wave of institutional money stays long BTC for decades, says EMJ Capital...
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.